Boulder, Colorado, USA, November 15, 2026
Ambrosia Biosciences has announced new nonclinical findings for two investigational oral small-molecule drug candidates, AMB-895 and AMB-131, targeting obesity and related metabolic disorders. The findings were presented through two scientific poster presentations at ObesityWeek 2026, the annual meeting of The Obesity Society. The research highlights the potential of developing differentiated oral therapies that could offer greater flexibility in dosing and expand treatment options for people living with obesity and metabolic conditions. AMB-895 is a novel oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist designed for potential once-weekly administration, while AMB-131 is an oral small-molecule glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist being investigated as a complementary approach to metabolic disease treatment. According to Ambrosia, both candidates demonstrated differentiated pharmacokinetic profiles and encouraging activity in preclinical models. The findings represent an important development in the company’s drug discovery pipeline, particularly as pharmaceutical researchers continue exploring oral alternatives to injectable metabolic therapies. However, both programmes remain at the nonclinical research stage, and their safety and effectiveness in humans have not yet been established.
AMB-895 Demonstrates Potential for Once-Weekly Oral GLP-1 Treatment
One of the major highlights from the presentations was the preclinical performance of AMB-895, an investigational oral small-molecule GLP-1 receptor agonist designed to provide sustained biological activity with once-weekly dosing. In a lean non-human primate (NHP) model, a single oral dose of 1 mg/kg demonstrated sustained target coverage above EC70 for more than one week, indicating prolonged engagement with the intended biological target. Further experiments evaluated the candidate through once-weekly oral administration over a 14-day period. The results demonstrated sustained weight reduction and decreased food intake in the animal model. At the 1 mg/kg dose, AMB-895 achieved an average weight reduction of 8% from baseline by Day 14. These findings provide preliminary evidence supporting the potential of the compound’s long-acting pharmacological profile. The development of oral GLP-1 receptor agonists with extended activity is an important research area because it could offer an alternative administration approach compared with frequently administered injectable therapies and existing daily oral medicines. Nevertheless, the observed weight reduction was achieved in non-human primates and should not be interpreted as evidence of weight-loss effectiveness in humans. Further studies will be necessary to establish the candidate’s pharmacokinetics, safety, tolerability and potential therapeutic benefits before clinical evaluation.
AMB-131 Shows Potential for Combination Obesity Therapy
The second programme, AMB-131, is a novel oral small-molecule antagonist targeting the GIP receptor. GIP is an incretin hormone involved in metabolic regulation, making its receptor an important target for research into obesity and related metabolic disorders. Ambrosia reported that AMB-131 demonstrated higher drug exposure and sustained target coverage at 24 hours in both mouse and non-human primate models. Additional preclinical experiments investigated its potential in combination with semaglutide, an established GLP-1 receptor agonist. In a mouse model of diet-induced obesity, AMB-131 enhanced semaglutide-induced weight loss, suggesting that GIP receptor antagonism may offer opportunities for developing combination-based metabolic treatments. This research is particularly relevant because pharmaceutical developers are increasingly investigating combinations of therapies that target different biological pathways involved in appetite regulation, energy balance and body weight management. Ambrosia believes that combining oral small-molecule agents with complementary mechanisms could provide opportunities to optimise treatment efficacy and tolerability. However, the findings remain preliminary, and further research will be required to determine whether the combination approach can produce meaningful clinical benefits in people with obesity. The company is continuing to investigate the pharmacological characteristics and development potential of its GIP receptor antagonist programme.
ObesityWeek 2026 Highlights Ambrosia’s Drug Discovery Pipeline
The two presentations at ObesityWeek 2026, held November 14–17, highlight Ambrosia’s continued investment in developing next-generation oral small-molecule therapies for obesity and cardiometabolic diseases. The AMB-895 research was presented as Poster 463, titled “Discovery and Nonclinical Profile of AMB-895, a Long-Acting and Novel Oral Small Molecule GLP-1R Agonist.” The AMB-131 findings were presented as Poster 470, titled “Discovery and Nonclinical Profile of AMB-131, a Novel, Oral Small Molecule GIP Receptor Antagonist.” Both presentations took place on November 15 during the Emerging Weight-Loss Therapies and Long-Term Outcomes poster session. Ambrosia is also advancing other metabolic research programmes, including AMB-702, its once-daily oral small-molecule GLP-1 receptor agonist, alongside investigational amylin agonist programmes. The company’s broader strategy focuses on structurally enabled drug design, medicinal chemistry and biological research to develop differentiated oral therapies. The AMB-895 and AMB-131 findings strengthen Ambrosia’s early-stage metabolic drug discovery portfolio and highlight new opportunities for oral obesity treatment development. Future preclinical studies and subsequent clinical investigations will determine whether these candidates can translate their encouraging animal-model results into safe and effective therapies for patients.
Source: Ambrosia Biosciences press release



